Connection

TAO WU to Antineoplastic Agents

This is a "connection" page, showing publications TAO WU has written about Antineoplastic Agents.
Connection Strength

0.355
  1. An albumin-prodrug injectable formulation for synergistic cancer immunotherapy. J Colloid Interface Sci. 2025 May 15; 686:1019-1032.
    View in: PubMed
    Score: 0.115
  2. Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. J Clin Invest. 2020 02 03; 130(2):981-997.
    View in: PubMed
    Score: 0.082
  3. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell. 2018 01 25; 172(3):578-589.e17.
    View in: PubMed
    Score: 0.071
  4. Salinomycin Exerts Anticancer Effects on PC-3 Cells and PC-3-Derived Cancer Stem Cells In Vitro and In Vivo. Biomed Res Int. 2017; 2017:4101653.
    View in: PubMed
    Score: 0.068
  5. Risk-dependent curability of radiotherapy for elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG). Cancer Med. 2018 12; 7(12):5952-5961.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.